Targeted drug significantly delays advanced breast cancer progression but increases toxicity, phase III trial reports
In a global phase 1 trial, trastuzumab rezetecan showed promising signs of fighting ERBB2-low metastatic breast cancer in patients who had already undergone extensive treatment. Also known as HER2-low breast cancer, this subtype is characterized by low levels of HER2, a growth factor protein that can still be targeted for treatment. Trastuzumab rezetecan is an antibody-drug conjugate (ADC) that…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
New microscopy platform enables imaging of neuronal activity at single-cell resolution at unprecedented tissue depth
United Kingdom
-
Living near water-pollution sources associated with rare brain disorder
United Kingdom
-
UCSF scientists develop smart CAR-T cells to fight childhood brain tumors
United Kingdom
-
Tiny corneal bumps reveal potential path toward treating severe vision loss
United Kingdom
-
Study shows income gaps drive disparities in universal healthcare access
United Kingdom
-
Inflammatory macrophages identified as drivers of chronic joint osteoarthritis
United Kingdom
-
Researchers identify protein that drives chronic inflammation in psoriasis
United Kingdom
-
Human challenge study reveals how preexisting immunity affects dengue
United Kingdom